A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

General Information

Summary This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.
Clinical trials phase Phase 2
Start date (estimated) 2023-03-24
End date (estimated) 2029-04-11
Clinical feature
Label age related macular degeneration
Link http://purl.obolibrary.org/obo/DOID_10871
Description A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05626114
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05626114
Other study identifiers
Name GR44251
Source weblink https://clinicaltrials.gov/ct2/show/NCT05626114
Study sites
Public contact
Email global-roche-genentech-trials@gene.com
Public email global-roche-genentech-trials@gene.com
First name Clinical Trials Hoffmann-La Roche
Phone +1 888-662-6728 (U.S. Only)
Sponsors Genentech, Inc.


Which differentiated cell type is used
Label retinal pigment epithelial cell
Link http://purl.obolibrary.org/obo/CL_0002586
Description An epithelial cell of the retinal pigmented epithelium.


Recruitment Status Recruiting
Estimated number of participants 60